1) defect model of rats was used for in vivo studies. |
2) of the literature resulted in 23 relevant studies. |
3) es, and extracting data from the selected studies. |
4) g criteria to be included for future EPFR studies. |
5) th average sample sizes of 716 across all studies. |
6) ld serve in effect as phase 0 and phase I studies. |
7) tion was not different in non-MA drinking studies. |
8) s well as for mechanistic pharmacokinetic studies. |
9) approach for quantitative pharmacokinetic studies. |
10) uman ROSMAP datasets and mouse microarray studies. |
11) in MRI scans from four neurodevelopmental studies. |
12) are commonly used in combination in mouse studies. |
13) is use aggregate level data from multiple studies. |
14) son r or the Hosmer-Lemeshow test in four studies. |
15) n generic NMAs that may contain multi-arm studies. |
16) eference lists were searched for relevant studies. |
17) summarized results of several independent studies. |
18) for a total of 69,350 subjects across all studies. |
19) were performed in n = 17 (63%) of the studies. |
20) re additional evidence from observational studies. |
21) oci (pQTL) and CCR2 expression QTL (eQTL) studies. |
22) mbers was not highlighted in the included studies. |
23) e therefore used for in vitro and in vivo studies. |
24) guide the conduct and critique of scoping studies. |
25) stematic, biogeographic, and evolutionary studies. |
26) measure may not feasibly handle multi-arm studies. |
27) ent steps and should be tested in further studies. |
28) genome-wide and phenome-wide association studies. |
29) m environmental sequencing and ecological studies. |
30) nvestment in regional longitudinal cohort studies. |
31) kes it difficult to compare results among studies. |
32) sociation with RH in contrast to previous studies. |
33) hat were not realized in other simulation studies. |
|